Cell Source Inc's Comment on Sales, Marketing and Customers
The company targets customers in the United States, Western Europe, China, and other major global markets. It maintains direct relationships with leading transplantation centers and has partnerships with global pharmaceutical companies, including arrangements for out-licensing or acquisition. Initial sales efforts focus on centers specializing in late-stage B-cell malignancies and high-volume hematopoietic stem cell transplantation (HSCT) facilities. The company plans to seek product approval initially in the US and Europe, with later entry into China and potentially Japan. Targeted market segments include blood cancers and kidney failure, selected based on unmet medical needs and technology relevance. Future product offerings may include applications in organ transplantation and custom Veto Cell developments for collaboration with other cell therapy treatments, such as those targeting NK cells, TCR, and blood cancers, aiming to address rejection and persistence challenges.
Cell Source Inc’s Comment on Sales, Marketing and Customers
The company targets customers in the United States, Western Europe, China, and other major global markets. It maintains direct relationships with leading transplantation centers and has partnerships with global pharmaceutical companies, including arrangements for out-licensing or acquisition. Initial sales efforts focus on centers specializing in late-stage B-cell malignancies and high-volume hematopoietic stem cell transplantation (HSCT) facilities. The company plans to seek product approval initially in the US and Europe, with later entry into China and potentially Japan. Targeted market segments include blood cancers and kidney failure, selected based on unmet medical needs and technology relevance. Future product offerings may include applications in organ transplantation and custom Veto Cell developments for collaboration with other cell therapy treatments, such as those targeting NK cells, TCR, and blood cancers, aiming to address rejection and persistence challenges.
Sources:
Cell Source Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cell Source Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cell Source Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
